ReviewNatural product reports2014
Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.
Review in Natural product reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- Asymmetric Deoxygenative Difunctionalization of 1,2-Dicarbonyl Compounds Enabled by Phosphinite and Chiral Salen-Molybdenum Catalyst Synergy.Angewandte Chemie (International ed. in English) · 2026Article
- Activity of Didesmethylrocaglamide in High Grade Serous Ovarian Cancer Using Preclinical In Vitro and In Vivo Models.Journal of natural products · 2026Article
- The continuing need for taxonomic input in phytochemical research.Journal of ethnopharmacology · 2026Review
- Silvestrol inhibits nasopharyngeal carcinoma cells and synergizes with CX-5461: Insights from a proteomics study.Molecular and clinical oncology · 2025Article
- Evaluation of the impact of Roclaglamide on MDA-MB-231 human breast adenocarcinoma cells by cell culture and molecular approaches.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Article
- Additional Bioactive Silvestrol Analogs from the Roots ofJournal of natural products · 2025Article
- Protein-RNA interactions mediated by silvestrol-insight into a unique molecular clamp.Nucleic acids research · 2024Article
- METTL3 as a master regulator of translation in cancer: mechanisms and implications.NAR cancer · 2024Review
- Halogenated Rocaglate Derivatives: Pan-antiviral Agents against Hepatitis E Virus and Emerging Viruses.Journal of medicinal chemistry · 2024Article
- A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer.Frontiers in immunology · 2024Review
- Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.Molecular cancer · 2023Article
- Strategies for the discovery of potential anticancer agents from plants collected from Southeast Asian tropical rainforests as a case study.Natural product reports · 2023Review
- DEAD-box RNA helicases with special reference to p68: Unwinding their biology, versatility, and therapeutic opportunity in cancer.Genes & diseases · 2023Review
- Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer.RSC medicinal chemistry · 2023Review
- Broad-Spectrum Antivirals Derived from Natural Products.Viruses · 2023Review
- eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- In silico study on the Hepatitis E virus RNA Helicase and its inhibition by silvestrol, rocaglamide and other flavagline compounds.Scientific reports · 2022Article
- Enzymatic and Molecular Characterization of Anti-Molecules (Basel, Switzerland) · 2022Article
- Discovery of Anticancer Agents of Diverse Natural Origin.Journal of natural products · 2022Article
- Comparative phytochemistry of flavaglines (= rocaglamides), a group of highly bioactive flavolignans fromPhytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Covering: 2006 to 2013. Investigations on the chemistry and biology of rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species during the period 2006-2013 are reviewed. Included are new phytochemical studies of naturally occurring rocaglamide derivatives, an update on synthetic methods for cyclopenta[b]benzofurans, and a description of the recent biological evaluation and mechanism-of-action studies on compounds of this type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.